SLC5A2 and myocardial infarction: Our study indicates that it is efficacious to start treatment with an SGLT2 inhibitor in the acute and subacute phase of myocardial infarction but should be interpreted in the context of the observational design using all patients in one country in contrast to the randomised clinical trials enrolling highly selected patients.11